AAV Manufacturing

Late-Phase Manufacturing

As your AAV program advances toward pivotal studies and commercialization, the manufacturing questions change. Is your process well understood? Can it perform consistently? Are you prepared for validation, PPQ, and the regulatory expectations ahead? Our late-phase experts help you answer those questions and build the process understanding and manufacturing readiness needed for commercial supply.

A Structured Path to Commercial Readiness

Preparing for commercial manufacturing brings together many interconnected activities. Our late-phase manufacturing packages help you understand what your program needs, identify potential gaps, and build a strategy for process characterization, validation, PPQ, and regulatory readiness.

Late-Phase Manufacturing Packages:

  1. Program Risk Assessment Stage I
    • Process Risk Assessment (PRA)
    • Materials Risk Assessment (MRA)
  2. Process Characterization Planning
  1. Scale Down Model Qualification
  2. Process Characterization
  3. Analytical Method Validation
  4. Program Risk Assessment Stage II
    • Parameter Criticality Assessment (PCA)
    • Process Failure Modes & Effects Analysis (pFMEA)
  5. Raw Material Qualification
  6. Engineering Studies
  7. PPQ Campaign
  1. CMC Data Package (PPQ Campaign Summary)
  2. Validation Master Plan
    • Container Closure Integrity Testing (CCIT)
    • Contamination Control Strategy (CCS)
    • Viral Clearance
    • & more
  3. Shipping Validation
  4. Leachables & Extractables (L&Es)
  5. PLI Readiness
  6. Commercial Supply Planning

From Feasibility to a Validated, Commercial-Ready Process

As your program advances, so do the expectations for how well your manufacturing process is understood, characterized, and controlled.

Process Characterization: Building Process Understanding

Before you can validate your process, you need to understand how it performs and which parameters matter most. Process characterization uses risk assessment, qualified scale-down models, and statistically designed studies to understand how process parameters and material attributes influence product quality and establish an appropriate control strategy. Our approach aligns with the industry-developed ARM/NIIMBL Project A-Gene framework.

Analytics Integrated Throughout

Analytical development strategy is developed alongside process characterization to support the volume, range of matrices, and process understanding required for late-phase studies.

PPQ & Process Validation

Once you understand your process, the next step is demonstrating that it can perform consistently. Process characterization provides the scientific foundation for process validation and PPQ readiness, helping establish the process understanding and control strategy needed as your program prepares for commercial manufacturing.

Facility and Infrastructure Readiness for Late-Phase Manufacturing

We’re enhancing our facility, equipment, quality systems, and digital infrastructure to support programs in late-phase production.

Facility & Capacity: Scaling for Late-Phase Programs

  • Bioreactor scales from 0.25 L scale-down models to 5,000 L
  • Expanding late-phase facility infrastructure, including new QC and Analytical Development lab space

Drug Product: Expanding Fill-Finish Capabilities

  • Cytiva Microcell fill-finish capabilities for clinical supply
  • Advancing implementation of Cytiva SA25 automated fill-finish for clinical and commercial supply

Data & Digital Infrastructure: Strengthening Operational Readiness

  • Building digital infrastructure to support commercial planning, materials, inventory, operations, and strengthening quality systems.
What is late-phase cGMP manufacturing for AAV gene therapies?
When should AAV developers begin preparing for commercial manufacturing?
What is involved in AAV process characterization?
How does process characterization support PPQ readiness?
What is required to prepare an AAV manufacturing process for PPQ?
How do analytical methods need to evolve for late-phase AAV manufacturing?
What is the difference between pivotal clinical and commercial AAV manufacturing?

Hot off the Forge